Bluebird Revises Business Priorities And Secures Upfront Cash From Bristol
Executive Summary
The company is deferring investment in a US commercial team and prioritizing R&D activities, but it outlined an accelerated path to approval for LentiGlobin in sickle cell disease.
You may also be interested in...
BMS/Bluebird Ready Abecma, First BCMA-Targeting CAR-T, For Initial Patients
Idecabtagene vicleucel for fifth-line multiple myeloma lags GSK’s BCMA-targeting ADC Blenrep, but it is months ahead of J&J/Legend’s CAR-T. Abecma is BMS’s second CAR-T approval this year.
Stock Watch: The Mixed History Of Biotech Company Separations
The path of spin-offs from loss-making biotech companies with weak investment propositions seems clouded with examples that often resulted in an appointment with the liquidator.
Finance Watch: Moderna Capitalizes On COVID-19 Vaccine Data Value Boost
Public Company Edition: Moderna leveraged its all-time high stock price to raise $1.34bn on the same day it reported data from a Phase I trial of its COVID-19 vaccine. Several other companies also took advantage of biopharma’s rising value.